459 related articles for article (PubMed ID: 36552725)
1. Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs.
Mukherjee AG; Wanjari UR; Gopalakrishnan AV; Katturajan R; Kannampuzha S; Murali R; Namachivayam A; Ganesan R; Renu K; Dey A; Vellingiri B; Prince SE
Cells; 2022 Dec; 11(24):. PubMed ID: 36552725
[TBL] [Abstract][Full Text] [Related]
2. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
3. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.
Rusu I; Pirlog R; Chiroi P; Nutu A; Puia VR; Fetti AC; Rusu DR; Berindan-Neagoe I; Al Hajjar N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293225
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
5. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.
Silva AKS; Peixoto CA
Cell Mol Life Sci; 2018 Aug; 75(16):2951-2961. PubMed ID: 29789866
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between PPARs and gut microbiota in NAFLD.
Wu L; Li J; Feng J; Ji J; Yu Q; Li Y; Zheng Y; Dai W; Wu J; Guo C
Biomed Pharmacother; 2021 Apr; 136():111255. PubMed ID: 33485064
[TBL] [Abstract][Full Text] [Related]
8. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
9. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
11. Roles of PPARs in NAFLD: potential therapeutic targets.
Tailleux A; Wouters K; Staels B
Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
14. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
Morishita A; Oura K; Tadokoro T; Fujita K; Tani J; Kobara H; Ono M; Himoto T; Masaki T
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833930
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
18. PPARs and nonalcoholic fatty liver disease.
Liss KH; Finck BN
Biochimie; 2017 May; 136():65-74. PubMed ID: 27916647
[TBL] [Abstract][Full Text] [Related]
19. Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.
Zaiou M
World J Gastroenterol; 2022 Sep; 28(35):5111-5128. PubMed ID: 36188722
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
